Clinical Trial Update: Safety and Feasibility of TA-CIN Vaccine in HPV16 Associated Cervical Cancer [Phase 1]

View source ↗

Summary

Phase 1 study assessing the safety and feasibility of the TA-CIN vaccine for HPV16-associated cervical cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• TA-CIN vaccine

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: HPV16 Associated Cervical Cancer | Phase 1 | Status: COMPLETED | Results posted: 2026-01-22